Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBITDA (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed EBITDA for 4 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 4.59% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, down 70.54% year-over-year, with the annual reading at -$3.0 million for FY2025, 70.54% down from the prior year.
  • EBITDA for Q4 2025 was $4.3 million at bioAffinity Technologies, up from -$2.2 million in the prior quarter.
  • The five-year high for EBITDA was $4.3 million in Q4 2025, with the low at -$2.6 million in Q1 2025.
  • Average EBITDA over 4 years is -$1.0 million, with a median of -$1.8 million recorded in 2023.
  • The sharpest move saw EBITDA plummeted 156.88% in 2023, then skyrocketed 290.77% in 2024.
  • Over 4 years, EBITDA stood at -$1.6 million in 2022, then crashed by 34.62% to -$2.2 million in 2023, then surged by 290.77% to $4.2 million in 2024, then increased by 4.59% to $4.3 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $4.3 million, -$2.2 million, and -$2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.